Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
2002 2
2003 3
2004 2
2005 2
2008 1
2009 1
2010 3
2011 4
2015 1
2017 1
2018 1
2019 1
2020 1
2021 3
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Frailty and Geriatric Medicine During the Pandemic.
Crosignani S, Fantinati J, Cesari M. Crosignani S, et al. Front Med (Lausanne). 2021 Jun 7;8:673814. doi: 10.3389/fmed.2021.673814. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34164415 Free PMC article.
Discovery of a novel series of selective macrocyclic PKCTheta inhibitors.
Crosignani S, Campos S, Bouix-Peter C, Harris C, Talbot E, Hu H, Wang S, Maclean J, Zanelli U, Taylor S, Foote K, Hacini-Rachinel F, Nicodeme E, Julia V. Crosignani S, et al. Bioorg Med Chem Lett. 2024 Mar 1;100:129630. doi: 10.1016/j.bmcl.2024.129630. Epub 2024 Feb 1. Bioorg Med Chem Lett. 2024. PMID: 38307441
Discovery of a novel series of CXCR3 antagonists.
Crosignani S, Missotten M, Cleva C, Dondi R, Ratinaud Y, Humbert Y, Mandal AB, Bombrun A, Power C, Chollet A, Proudfoot A. Crosignani S, et al. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3614-7. doi: 10.1016/j.bmcl.2010.04.113. Epub 2010 Apr 28. Bioorg Med Chem Lett. 2010. PMID: 20483605
Discovery of a novel series of potent S1P1 agonists.
Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, Françon B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF. Crosignani S, et al. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1516-9. doi: 10.1016/j.bmcl.2010.01.102. Epub 2010 Jan 25. Bioorg Med Chem Lett. 2010. PMID: 20149651
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B, Driessens G, Bartlett D, Cai D, Cauwenberghs S, Crosignani S, Dalvie D, Denies S, Dillon CP, Fantin VR, Guo J, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Pirson R, Rabolli V, Ray C, Streiner N, Torti VR, Tsaparikos K, Van den Eynde BJ, Wythes M, Yao LC, Zheng X, Tumang J, Kraus M. Gomes B, et al. Among authors: crosignani s. Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19. Mol Cancer Ther. 2018. PMID: 30232146
29 results